Cellceutix Corp., a Beverly biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, said it plans to collaborate with Beth Israel Deaconess Medical Center on a research project that will explore the potential of a Cellceutix drug candidate for treating certain types of cancer.
According to Cellceutix, Beth Israel wants to look into the the nuclear and mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.
The p53 signaling pathway is a crucial regulator of cell cycle and apoptosis.
On its website, Cellceutix says that its drug candidate Kevetrin has “demonstrated the potential for a major breakthrough in cancer research by exhibiting an activation of p53.”
The collaborative studies are independent from the planned clinical trials for Kevetrin, Cellceutix said in a press release.
In a statement, Cellceutix chief executive Leo Ehrlich said: “Beth Israel Deaconess Medical Center will be researching Kevetrin for indications in addition to those which we will be studying in our company-sponsored clinical trials. If they collect promising data in their research of Kevetrin in melanoma and renal cell carcinoma, additional grant and government funding may become available to further study these separate indications, saving us substantial time and money towards the end goal of commercialization.”
Chris Reidy can be reached at email@example.com.